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Objectives
• To assess prospectively the safety and efficacy of
transurethral resection of the prostate (TURP) for the
treatment of lower urinary tract symptoms attributable to
benign prostatic hyperplasia (BPH) in patients who have
undergone renal transplantation (RT).
• To assess the impact of TURP on renal graft function.
Patients and Methods
• Urological and renal functional outcomes of TURP
performed in RT recipients for treatment of lower
urinary tract obstruction attributable to BPH were
prospectively assessed in a series of 32 consecutive
patients with follow-up of 48 months.
• Maximum urinary flow rate (Qmax) at uroflowmetry,
International Prostate Symptom Score (IPSS), post-void
residual urine volume (PVR), haemoglobin and serum
creatinine (sCr) levels were recorded before TURP and 1,
6, 24 and 48 months after the procedure. The trends in
these variables after TURP were evaluated.
• Early and delayed complications were assessed and
graded according to the Clavien classification system.
Results
• TURP was performed at a mean of 6 months after RT.
• No intraoperative complications occurred. Seven
postoperative complications were observed (21.9%): two
Clavien grade II and five Clavien grade IIIa.
• Qmax, IPSS and PVR improved significantly after surgery
and the improvement was maintained until 48 months.
No patient required a repeat TURP during follow-up.
• SCr levels significantly decreased 1 and 6months after TURP
and did not significantly increase at long-term follow-up.
Conclusions
• TURP for lower urinary tract obstruction attributable to
BPH in RT recipients is safe and effective since it
improves urinary flow, bladder emptying and related
urinary symptoms.
• TURP allows an early significant improvement of graft
function that is maintained at a follow-up of 48 months.
Keywords
benign prostatic hyperplasia, bladder outlet obstruction,
lower urinary tract symptoms, renal functional outcomes,
renal transplantation, transurethral resection
Introduction
The mean age of patients undergoing renal transplantation
(RT) has been increasing in recent years [1,2]. According to
the 2006 United States Renal Data System Annual Report,
the proportion of RT recipients >60 years old increased
from 10.4% in 1994 to 20.7% in 2004 [3]. This reflects the
increasing age of the overall population and of patients on
renal replacement therapy [1,2].
Functional outcomes of transplanted kidneys in elderly
patients are satisfactory overall [4,5] and recent studies on
series of older RT recipients reported similar graft survival
rates compared with those observed for younger recipients
[6–9]; however, the widespread use of extended-criteria
donors in this setting (‘old-for-old’ allocation) makes these
grafts prone to developing chronic interstitial fibrosis
owing to calcineurin-inhibitor nephrotoxicity or chronic
urinary tract obstruction [10,11].
Benign prostatic hyperplasia is a common disease in elderly
men. It is estimated that in the USA >70% of men aged
60–69 years are affected by BPH [12]. The incidence of
bladder outlet obstruction (BOO) attributable to benign
prostatic hyperplasia (BPH) among RT recipients is often
underestimated as patients undergoing dialysis are oliguric
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or anuric. Nevertheless, after RT and restoration of diuresis,
urinary obstruction and related lower urinary tract
symptoms (LUTS) become evident [13], being responsible
for patient bother and risk for graft function.
Today, TURP is considered to be the ‘gold standard’
treatment for LUTS attributable to BPH and its safety and
efficacy have been confirmed in large series [14,15]. Studies
in the literature have reported that TURP after RT is a safe
procedure, but these studies were focused only on
urological outcomes and had a short mean follow-up.
Furthermore, to our knowledge, no information is available
about the effects of TURP on renal functional outcomes
after RT.
The aim of the present prospective study was to evaluate
the long-term safety and efficacy of TURP performed after
RT and to assess the impact of this procedure on graft
function.
Patients and Methods
Patients
From November 1998 to July 2009, 636 patients with
end-stage renal disease (246 women and 390 men)
underwent cadaveric or living donor RT at our centre.
Immunosuppressive therapy was based on steroids,
mycophenolate mofetil and cyclosporine in the first 51
patients and on steroids, mycophenolate mofetil (or
mycophenolic acid) and tacrolimus in the remaining
patients. An induction was performed in all patients with
basiliximab (20 mg on postoperative day 0 and 4) and
calcineurin inhibitor introduction was either immediate or
delayed until serum creatinine (sCr) decreased below
2 mg/dL. A histological evaluation of the graft according to
Karpinsky score was performed in all donors aged >50
years before transplantation [16].
Overall, 103/314 (32.8%) male patients >40 years developed
LUTS after RT. In all cases medical treatment with
a-blockers (tamsulosine or alfuzosine) and/or 5-a
reductase inhibitors (5-ARIs; finasteride or dutasteride) was
initially recommended. Notably, 17/103 patients (16.5%)
had already been on treatment with an a-blocker
(doxazosin) for hypertension before development of
significant LUTS and were given additional 5-ARIs when
needed.
Patients underwent urological evaluation at 3 and 6 months
after the start of medical therapy and every 12 months
thereafter. According to our internal guidelines, TURP was
indicated during follow-up in case of urinary retention
requiring a permanent indwelling urethral catheter or in
the presence of post-void residual urine volume (PVR)
>100 mL, maximum urinary flow rate (Qmax) 10 mL/s,
increased (3 points) International Prostate Symptom
Score (IPSS), new onset of significant hydronephrosis at
transplant ultrasonography or increasing sCr values in the
absence of other reasons for worsening renal function.
Urological Assessment before TURP
Before TURP all patients underwent a thorough urological
evaluation. Digital rectal examination (DRE), serum PSA
testing, IPSS assessment, urine analysis with cultures and
sensitivity, TRUS, uroflowmetry and PVR measurement
were carried out in all patients. Urodynamic tests were
performed in selected patients.When a prostate cancer was
suspected based on elevated PSA values and/or suspicious
DRE, patients were scheduled for prostate biopsy. Patients
with evidence of prostate cancer at pathology or with LUTS
attributable to neurological disorders at urodynamic tests
were excluded from the study.
Nephrological Assessment before TURP
A thorough nephrological evaluation was carried out
before TURP to exclude other causes of renal impairment
and to identify the best time for intervention. In all patients
with persistently impaired renal function and proteinuria,
TURP was deferred so that renal biopsy and adequate
treatment (e.g. steroid pulse therapy in the presence of
acute rejection) could be performed as needed. Only
patients without evidence of active nephrological problems
underwent TURP. In all patients, immunosuppressive
therapy was assessed before intervention; in mTOR-treated
patients the drug was withdrawn at least 1 week before
TURP and re-started at least 1 week afterwards to avoid
interference with surgical healing. Steroid dose and
tacrolimus levels were increased in these cases to provide
sufficient immunosupression in the perioperative period.
Steroids were administered i.v. on the day of intervention
(switch from oral prednisone to an equivalent dose of i.v.
methylprednisolone) and then restarted orally in all
patients.
TURP Technique
We performed TURP under spinal or general anaesthesia.
Perioperative antibiotic prophylaxis was performed
30 min before the procedure and continued on the first
postoperative day.We used ampicilline-sulbactam 3 g if no
urinary tract infection (UTI) was detected at preoperative
cultures and other antibiotics according to sensitivity tests
in the case of positive cultures. TURP was performed by
different surgeons using a 26 F continuous-flow monopolar
or bipolar resectoscope according to the standard
techniques. The decision to perform a monopolar or
bipolar TURP was based on the estimated adenoma volume
at TRUS and on surgeon preference. At the end of the
procedure a 22–24 F Dufour catheter was placed with
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continuous bladder irrigation until the morning after
surgery. The catheter was removed on the second
postoperative day if the urine was clear. PVR was always
tested before patient discharge.
For each patient we collected the following preoperative
variables: serum PSA, IPSS, Qmax at uroflowmetry, PVR,
haemoglobin (Hb) and sCr levels. For patients with an
indwelling urethral catheter before TURP, we considered
the sCr level measured before the catheter was placed to be
the preoperative sCr. Recorded operative variables included
type of resection (monopolar vs bipolar), operating time
and volume of prostate tissue resected. Length of hospital
stay, catheterization time and pathology of the tissue
resected were also collected. Postoperative complications
were recorded and graded according to the Clavien–Dindo
classification [17]. Early and delayed complications were
defined as those that occurred <24 h and >24 h after TURP,
respectively.
Follow-up
Patients with a minimum follow-up of 48 months after
TURP were considered eligible for the study. Follow-up
consisted of physical examination, DRE, urine analysis with
cultures, uroflowmetry, PVR measurement and IPSS at 1, 6,
24 and 48 months. Proteinuria, Hb and sCr levels were
tested according to the same time schedule.
Statistical Analysis
Statistical analyses and graphics were performed using SPSS
v. 15.0 (SPSS Inc., Chicago, IL, USA) and Statistica v. 7
(StatSoft Inc., Tulsa, OK, USA). Normality distribution was
assessed using the Kolmogorov–Smirnov and the
Shapiro–Wilk tests, and visually by histogram and kernel
density plot. In the presence of skewness and considerable
departure from normal distribution, data were expressed as
median values with interquartile ranges (IQRs). Differences
in Hb between two paired samples (before and after TURP)
were performed using the Wilcoxon signed-rank method.
Friedman’s test was used to compare levels of sCr, PVR,
and Qmax before and after 1, 6, 24 and 48 months. Changes
in sCr were also evaluated in relation to the sCr critical
difference, which indicates, for a stated probability level, the
change needed between two serial results from the same
individual to be significantly different; sCr critical
difference was calculated according to the following
formula:
CD CVi CVa 1 2% . ,= × +( )2 77 2 2
with 2.77 depending on the selected probability of 95%, and
where CD% represents the sCR critical difference, and CVi
and CVa indicate the intra-individual variation and
analytical variation, respectively, specifically related to the
laboratory where tests were performed. For a CVi and CVa
of 4.3% and 3.8%, respectively, the sCr critical difference
was 15.9%.
Results
A total of 32 patients who underwent TURP after RT at our
centre with a minimum follow-up of 48 months were
included in the study. The median (IQR) time between RT
and TURP was 6 (3–14) months. Patient characteristics are
shown in Table 1. Overall, five patients had an indwelling
urethral catheter placed before TURP and four patients
underwent urodynamic tests without evidence of
neurogenic voiding disorders. No patient had significant
hydronephrosis of the transplanted kidney before TURP.
Thirteen patients (40.6%) underwent a biopsy of the
transplanted kidney before TURP because of persistently
impaired renal function and proteinuria. Immunological
lesions were seen in five patients (three cases of chronic
transplant glomerulopathy and two cases of acute
cell-mediated rejection) and required treatment before
TURP. Nephrotoxicity lesions were observed in five patients
and aspecific lesions in the remaining ones. At the time of
intervention all patients were receiving steroids with a
median (IQR) prednisone dose of 5 (2.5–10) mg/day.
Thirty out of 32 (93.8%) patients were on a calcineurin
inhibitor-based regimen (tacrolimus in all patients except
one, who was on cyclosporine A) and 7/32 (21.9%) were
taking an mTOR-inhibitor (rapamycin). Furthermore, 9/32
(28.1%) patients were under treatment with antiplatelet
agents which were withdrawn 1 week before TURP and
replaced with low-molecular-weight heparin until 2 weeks
after TURP. No patient was on anticoagulant therapy.
In 21 (65.6%) and 11 cases (34.4%), TURP was performed
with a monopolar and bipolar resectoscope, respectively.
The median (IQR) operating time was 41 (33–56) min and
the median (IQR) volume of tissue resected was 28 (22–34)
g. The median (IQR) catheterization time and hospital stay
Table 1 Preoperative characteristics of the 32 patients in the study.
Characteristic Median (IQR)
Age, years 58 (48–64)
Time on dialysis before RT, months 54 (22–81)
Residual diuresis before RT, mL 100 (50–200)
Preoperative Qmax, mL/s 9 (4.3–10)
Preoperative IPSS 15 (12–19)
Preoperative PVR, mL 140 (80–200)
Preoperative PSA, ng/mL 1.24 (0.5–1.45)
Volume of adenoma at TRUS, mL 26 (16–36)
Preoperative sCr, mg/dL 2.4 (1.8–2.7)
Preoperative proteinuria, g 0.2 (0.1–0.4)
Preoperative Hb level, g/dL 11.8 (9.9–13.2)
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were 1 (1–2) and 3 (3–4) days, respectively. Pathology
confirmed BPH in all cases and no incidental carcinoma
was detected.
No intraoperative complications were observed.
Postoperative complications were observed in seven
patients (21.9% [Table 2]). Early complications occurred in
two patients (6.3%). A patient with history of
beta-thalassemia developed fever >38 °C on the first
postoperative day. The antibiotic therapy was changed with
resolution of hyperthermia. Another patient experienced
persistent haematuria with a decrease in Hb levels (7 g/dL)
and underwent blood transfusions. No transurethral
resection syndrome occurred in the postoperative period.
Delayed complications occurred in five patients (15.6%).
Three patients developed acute urinary retention at
catheter removal. In all patients, a 16-F Foley urethral
catheter was placed and maintained for 48 h with no
further episodes of retention. Two patients developed a
bulbar urethral stricture 6 months after the procedure. In
both cases the stricture was successfully treated with laser
visual internal urethrotomy. No patient required repeat
endoscopic procedures during follow-up. All early
complications were Clavien grade II and all delayed
complications were Clavien grade IIIa.
The median (IQR) follow-up was 64 (48–125) months.
Preoperative and postoperative variables at the different
follow-up points are shown in Table 3. Postoperative Qmax
was significantly higher (P < 0.001), and IPSS and PVR
were significantly lower than preoperative values (P <
0.001). Qmax, IPSS and PVR values remained stable until 48
months (Fig. 1). No significant Hb reduction was observed
after TURP, while Hb level was significantly higher at 24
and 48 months follow-up compared with the preoperative
value (P < 0.001).
Patients’ sCr levels were significantly lower 1 and 6 months
after TURP (P < 0.001) and were slightly higher at 24 and
48 months (Fig. 2); however, sCr at 48 months after TURP
was still significantly lower compared with preoperative
values and not significantly different compared with sCr
values recorded at 6- and 24-month follow-ups. It is
noteworthy that 52 and 79% of patients had a reduction in
sCr levels beyond the critical difference after 1 and 6
months, respectively.
A comparative analysis with a control group of
age-matched transplanted patients who did not undergo
Table 2 Early (<24 h after TURP) and delayed (>24 h after TURP)
complications (n = 32).
Complication n (%) Treatment Clavien
grade
Early
Anaemia 1 (3.1) Blood transfusion II
Hypertermia (>38 °C) 1 (3.1) Antibiotic therapy II
Delayed
Acute urinary retention 3 (9.4) Bladder catheterization IIIa
Bulbar urethral stricture 2 (6.2) Visual internal urethrotomy IIIa
Fig. 1 Trend in peak flow rate (Qmax) at uroflowmetry during follow-up
of TURP.
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Table 3 Urological and renal functional outcomes during follow-up of TURP.
Preoperative 1 Month 6 Months 24 Months 48 Months
Median (IQR; min–max)
IPSS
15 (12–19; 11–20) 4* (0–5; 0–6) 3* (0-4; 0–5) 4* (0–6; 0–6) 3* (0–6; 0–6)
Median (IQR; min–max)
Qmax, mL/s
9.5 (7.0–10.0; 4.3–27.0) 21.0* (18–24; 16–32) 20.5* (18-24; 16–32) 19.5* (17–24.7; 17–33) 20* (16.5–22; 15–44)
Median (IQR; min–max)
PVR, mL
100 (100–150, 70–400) 0* (0–0; 0–40) 0* (0–0; 0–0) 0* (0–0; 0–50) 0* (0–0; 0–50)
Median (IQR; min–max)
Hb, g/dL
11.8 (9.9–13.2, 8.9–16.6) 11.5 (10.1–13.4, 8.3–14.8) 12.0 (11.5–14.2, 9.9–16.0) 12.8*† (11.7–14.5; 9.5–16) 13.0*† (12.0–14.0, 11.0–16.6)
Median (IQR; min–max)
SCr, mg/dL
2.4 (1.85–2.77; 1.2–8.8) 1.9* (1.5–2.35, 1.0–3.1) 1.7* (1.2–2.1, 1.0–3.0) 2* (1.4–2.3; 1.0–2.8) 2* (1.5–2.3, 0.8–2.4)
*Significant vs preoperative (P < 0.001). †Significant vs postoperative with correction for multiple comparisons (P < 0.001).
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TURP showed that sCr was significantly higher in patients
awaiting TURP compared with control patients 6 months
after RT (2.63 vs 1.69 mg/dL, P < 0.001). Conversely, there
was no significant difference between the sCr levels of
patients who underwent TURP and those of control
patients at 48-month follow-up (sCr = 1.9 vs 1.69 mg/dL,
P = 0.13).
Five patients (15.6%) underwent a renal biopsy for clinical
reasons after TURP; immunological lesions (chronic
transplant glomerulopathy) were detected in one patient,
while aspecific chronic vasculopathy without signs of
chronic rejection was the predominant finding in the
remaining patients.
Discussion
The incidence of end-stage renal disease increases with
advancing age. Owing to low survival rates and the
comparatively poor quality of life of patients in dialysis, RT
has been increasingly performed in older patients over the
past decade [1,2].
Although transplantation has been shown to be a good
option for renal replacement therapy also in this category
of patients [5–7], with graft survival outcomes that are
similar to those of younger recipients, older RT recipients
are more likely to have comorbidities that can affect graft
survival and patient quality of life. BPH is a chronic
condition that is associated with progressive LUTS
attributable to BOO in aging men. These symptoms affect
~75% of patients in the seventh decade of life [12]. It is
therefore not surprising that Tsaur et al. [18] reported a
high incidence of voiding dysfunctions largely attributable
to urinary obstruction caused by BPH in male RT
recipients aged 60 years. LUTS are frequently experienced
in this category of patients after RT while their presence is
generally underestimated in patients with uraemia of the
same age in dialysis owing to the decreased or absent
diuresis [13]. The presence of severe BOO is worrisome in
transplanted patients since this condition can lead to
urinary retention with high PVR levels, recurrent UTIs and
progressive deterioration of renal function. The median sCr
level of patients in our series before TURP was found to be
significantly higher than the median sCr level of an
age-matched population without signs of chronic urinary
obstruction 6 months after transplantation. Chronic
urinary obstruction can affect graft function, either by
increasing urethral resistances to urinary flow or by
affecting glomerular filtration rate (GFR) [19].
The current gold standard treatment for BPH and related
symptoms is TURP [15]. This is based on consistent data in
the literature supporting the safety and efficacy of this
procedure [14].Although transurethral incision of the prostate
is performed by some authors to relieve BOO after RT [20], at
our centre TURP is the preferred option for the treatment of
LUTS attributable to BPH in transplanted patients.
Only few, retrospective series of TURP in RT recipients
have been reported in the literature. In 1992, Reinberg
et al. [21] retrospectively compared the functional
outcomes of eight patients who underwent TURP within
10 days of RT with those of another group of patients
who did not undergo prostate surgery, and observed no
significant difference between the groups in terms of graft
and patient survival; however, there was a 25% incidence
of major postoperative complications after TURP
(including one mortality). With the improvement in
TURP technique, other authors subsequently reported the
efficacy of TURP in the treatment of BOO after RT
without significant risk of complications in the presence
of preoperative and postoperative sterile urinary cultures
[22,23]. Although these studies were based on a low
number of cases, a single institutional study very recently
reported 70 patients who underwent TURP for urinary
retention after RT. The authors identified patient age >60
years and duration of dialysis >120 months as significant
predictors of urinary retention requiring TURP in this
category of patients [24]. Finally, in a retrospective chart
review of a large cohort of 23 622 recipients, Hurst et al.
[25] observed that 7.3% of patients underwent TURP after
RT. At multivariate analysis, BPH was independently
associated with the incidence of acute urinary retention
episodes, UTIs and graft loss.
All these studies were retrospective, focused mainly on the
assessment of urological outcomes and have a relatively
short follow-up. The present study represents, to our
knowledge, the first prospective assessment of long-term
urological and functional results of TURP after RT.
Fig. 2 Trend in sCr levels during follow-up of TURP.
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In the present series, 32.8% of male recipients aged >40
years developed LUTS after RT, which is consistent with the
observations of Tsaur et al. [18] and emphasizes the clinical
importance of chronic urinary obstruction management in
transplanted patients.
Most patients with LUTS attributable to BPH can be
initially treated with medical therapy, either with
a-blockers, 5-ARIs or a combination of both [15]. At our
centre, patients are scheduled for TURP only after clinical
evidence of failure of a trial of medical treatment. This
represents our policy both in the general population and in
transplant recipients with LUTS.We believe this is
appropriate to avoid surgical overtreatment of patients with
moderate urinary obstruction and at the same time to select
patients that are most likely to benefit from endoscopic
resection.
In the present series, TURP was confirmed as a safe
procedure. No cases of transurethral resection syndrome
occurred. This can be explained by the relatively low
median size of the adenomas resected and by the
employment of continuous flow resectoscopes and bipolar
technology for TURP of larger prostates. Minor (Clavien
grade II) early complications were observed only in two
patients, including one case of bleeding requiring blood
transfusion and one of fever requiring modification of the
antibiotic regimen.
According to major urological guidelines the duration of
perioperative prophylaxis for a TURP should be ideally
minimized to a single preoperative dose [26]; however,
because of the higher risk of infections in the transplanted,
immunocompromised population, we preferred to extend
the administration of i.v. antibiotics to the entire first
postoperative day. Our policy seemed to be effective as only
one case of UTI (3.1%) was observed postoperatively in the
present series.
Delayed postoperative complications were observed in
15.6% of cases, including three urinary retentions after
catheter removal and two urethral strictures. All these
complications required an invasive treatment (re-insertion
of a urethral catheter or visual internal urethrotomy under
regional anaesthesia) and are therefore classified as Clavien
grade IIIa; however, all cases of postoperative urinary
retention were attributable to oedema or clots and resolved
spontaneously after a few days of further catheterization.
No re-TURP was needed during follow-up, confirming the
success of the procedure. The higher incidence of
postoperative strictures compared with other series of
TURP in the general population may be simply attributable
to the small number of patients in the present study [27].
Regarding urological outcomes, the present study clearly
confirms the clinical efficacy of TURP in RT recipients.
Urinary flow, bladder emptying and related urinary
symptoms improved significantly after TURP and this
improvement was maintained at long-term follow-up. In
particular, median Qmax at uroflowmetry increased from
9.5 mL/s preoperatively to 21 mL/s postoperatively (P <
0.001), and median IPSS score decreased from 15
preoperatively to 4 postoperatively (P < 0.001). No
significant decrease in Qmax or increase in IPSS score was
observed at 24- or 48-month follow-up (Table 3; Fig. 2).
Five out of 32 (15.6%) patients continued chronic
treatment with a-blockers (doxazosin) for hypertension
after TURP, potentially biasing the results, but as these men
were taking the same drug before TURP, this was unlikely
to have had a significant influence on the degree of
improvement of the urological outcomes.
Until now, no prospective and thorough assessment of the
efficacy of TURP on renal function at short- and long-term
follow-up has been available in the literature. The present
study shows that renal function of transplanted patients
who underwent TURP for LUTS attributable to BPH
improves at short-term follow-up. In fact, median sCr levels
showed a significant and progressive decline in the first 6
months after TURP (2.4 mg/dL preoperatively; 1.9 mg/dL 1
month after TURP; and 1.7 mg/dL 6 months after TURP;
P < 0.001). The median sCr level subsequently slightly
increased (2 mg/dL at 24–48 months), but remained
comparable with that observed in the postoperative period
confirming a satisfactory long-term graft function. Since
urological outcomes were stable over time confirming the
absence of recurrent urinary obstruction, the relative
increase in sCr levels 24–48 months after RT is probably
explained by the onset of new conditions affecting renal
function. Furthermore, no significant difference in sCr
levels at long-term follow-up was observed between
patients who underwent TURP after RT in the present
series and an age-matched population of transplanted
patients without signs of chronic urinary obstruction.
Although the two groups were not matched for
immunological parameters, immunosuppressive protocol
and comorbidities such as diabetes and cardiovascular
disease, this also suggests that the beneficial effects of
TURP on renal function are maintained over time.
In summary, the present study confirms the safety and
long-term efficacy of TURP in the treatment of BPH after
RT. TURP relieves BOO and significantly decreases related
LUTS in the postoperative period. The benefits for
urological outcomes are maintained until 48 months.
Furthermore, the study shows a significant improvement of
sCr levels in the postoperative months, with no significant
worsening at long-term follow-up. Larger series of TURP in
RT recipients with urodynamic confirmation of the
presence and degree of urinary obstruction are needed to
confirm our findings.
Outcomes of TURP in kidney transplant recipients
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